HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Genotyping microarray for CSNB-associated genes.

AbstractPURPOSE:
Congenital stationary night blindness (CSNB) is a clinically and genetically heterogeneous retinal disease. Although electroretinographic (ERG) measurements can discriminate clinical subgroups, the identification of the underlying genetic defects has been complicated for CSNB because of genetic heterogeneity, the uncertainty about the mode of inheritance, and time-consuming and costly mutation scanning and direct sequencing approaches.
METHODS:
To overcome these challenges and to generate a time- and cost-efficient mutation screening tool, the authors developed a CSNB genotyping microarray with arrayed primer extension (APEX) technology. To cover as many mutations as possible, a comprehensive literature search was performed, and DNA samples from a cohort of patients with CSNB were first sequenced directly in known CSNB genes. Subsequently, oligonucleotides were designed representing 126 sequence variations in RHO, CABP4, CACNA1F, CACNA2D4, GNAT1, GRM6, NYX, PDE6B, and SAG and spotted on the chip.
RESULTS:
Direct sequencing of genes known to be associated with CSNB in the study cohort revealed 21 mutations (12 novel and 9 previously reported). The resultant microarray containing oligonucleotides, which allow to detect 126 known and novel mutations, was 100% effective in determining the expected sequence changes in all known samples assessed. In addition, investigation of 34 patients with CSNB who were previously not genotyped revealed sequence variants in 18%, of which 15% are thought to be disease-causing mutations.
CONCLUSIONS:
This relatively inexpensive first-pass genetic testing device for patients with a diagnosis of CSNB will improve molecular diagnostics and genetic counseling of patients and their families and gives the opportunity to analyze whether, for example, more progressive disorders such as cone or cone-rod dystrophies underlie the same gene defects.
AuthorsChristina Zeitz, Stephan Labs, Birgit Lorenz, Ursula Forster, Janne Uksti, Hester Y Kroes, Elfride De Baere, Bart P Leroy, Frans P M Cremers, Mariana Wittmer, Maria M van Genderen, José-Alain Sahel, Isabelle Audo, Charlotte M Poloschek, Saddek Mohand-Saïd, Johannes C Fleischhauer, Ulrike Hüffmeier, Veselina Moskova-Doumanova, Alex V Levin, Christian P Hamel, Dorothee Leifert, Francis L Munier, Daniel F Schorderet, Eberhart Zrenner, Christoph Friedburg, Bernd Wissinger, Susanne Kohl, Wolfgang Berger
JournalInvestigative ophthalmology & visual science (Invest Ophthalmol Vis Sci) Vol. 50 Issue 12 Pg. 5919-26 (Dec 2009) ISSN: 1552-5783 [Electronic] United States
PMID19578023 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • CABP4 protein, human
  • CACNA1F protein, human
  • CACNA2D4 protein, human
  • Calcium Channels, L-Type
  • Calcium-Binding Proteins
  • Eye Proteins
  • GNAT1 protein, human
  • NYX protein, human
  • Proteoglycans
  • Receptors, Metabotropic Glutamate
  • metabotropic glutamate receptor 6
  • Rhodopsin
  • Cyclic Nucleotide Phosphodiesterases, Type 6
  • PDE6B protein, human
  • Heterotrimeric GTP-Binding Proteins
  • Transducin
Topics
  • Adolescent
  • Calcium Channels, L-Type (genetics)
  • Calcium-Binding Proteins (genetics)
  • Child
  • Cyclic Nucleotide Phosphodiesterases, Type 6 (genetics)
  • DNA Mutational Analysis
  • Eye Proteins (genetics)
  • Female
  • Gene Expression Profiling
  • Genotype
  • Heterotrimeric GTP-Binding Proteins (genetics)
  • Humans
  • Male
  • Mutation
  • Night Blindness (congenital, genetics)
  • Oligonucleotide Array Sequence Analysis
  • Pedigree
  • Polymerase Chain Reaction
  • Proteoglycans (genetics)
  • Receptors, Metabotropic Glutamate (genetics)
  • Retinal Diseases (congenital, genetics)
  • Rhodopsin (genetics)
  • Transducin

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: